APO Research
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Antibody Service

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Recombinant Antibody Service Market Outlook and Growth Opportunities 2026

11 April 2026Not stated

Choose your research edition.

Industry ResearchRecombinant Antibody Service Industry Research Report 2026145 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Antibody Service Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal Recombinant Antibody Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Antibody Service Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Recombinant Antibody Service Market Analysis and Forecast 2026-2032237 pages · $4,950 USD

Market perspective

The global Recombinant Antibody Service market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Recombinant Antibody Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Recombinant Antibody Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Recombinant Antibody Service is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Recombinant Antibody Service market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Recombinant Antibody Service market include GenScript Biotech Corporation, Abcam plc, Creative Biolabs, Absolute Antibody Ltd., Thermo Fisher Scientific, ProteoGenix, Bio-Rad Laboratories, Rockland Immunochemicals Inc. and RayBiotech, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Recombinant Antibody Service market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Recombinant Antibody Service and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Recombinant Antibody Service revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Recombinant Antibody Service market.

Recombinant Antibody Service Segment by Company

GenScript Biotech Corporation

Abcam plc

Creative Biolabs

Absolute Antibody Ltd.

Thermo Fisher Scientific

ProteoGenix

Bio-Rad Laboratories

Rockland Immunochemicals Inc.

RayBiotech, Inc.

Novoprotein Scientific Inc.

Sino Biological

Abnova

ACROBiosystems

Fitzgerald Industries International

Boster Biological Technology Co., Ltd.

Azenta Life Sciences

R&D Systems

Abcam

WuXi Biologics

Cell Signaling Technology, Inc.

Meridian Life Science Inc.

MabPlex Inc.

ProMab Biotechnologies

LakePharma(Curia)

Profacgen

Atlas Antibodies

Proteintech

BioLegend

OriGene Technologies

Biointron Biological

Detai Bio-Tech

FITGENE

Cusabio

GentleGen

TekBiotech

Recombinant Antibody Service Segment by Type

Antibody Discovery & Design Service

Recombinant Expression Service

Antibody Purification & Characterization Service

Recombinant Antibody Service Segment by Application

Biopharmaceuticals

Diagnostics

Research

Therapeutics

Recombinant Antibody Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Recombinant Antibody Service status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Recombinant Antibody Service key companies, revenue, market share, and recent developments.

3. To split the Recombinant Antibody Service breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Recombinant Antibody Service market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Recombinant Antibody Service significant trends, drivers, influence factors in global and regions.

6. To analyze Recombinant Antibody Service competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Antibody Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Antibody Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Antibody Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Recombinant Antibody Service industry.

Chapter 3: Detailed analysis of Recombinant Antibody Service company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Recombinant Antibody Service in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Recombinant Antibody Service in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Recombinant Antibody Service Industry Trends Table 2. Recombinant Antibody Service Industry Drivers Table 3. Recombinant Antibody Service Industry Opportunities and Challenges Table 4. Recombinant Antibody Service Industry Restraints Table 5. Global Recombinant Antibody Service Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Recombinant Antibody Service Revenue Share by Company (2021-2026) Table 7. Global Recombinant Antibody Service Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Recombinant Antibody Service Key Company Manufacturing Base & Headquarters Table 9. Global Recombinant Antibody Service Company, Product Type & Application Table 10. Global Recombinant Antibody Service Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Recombinant Antibody Service by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Antibody Discovery & Design Service Table 15. Significant Companies of Recombinant Expression Service Table 16. Significant Companies of Antibody Purification & Characterization Service Table 17. Global Recombinant Antibody Service Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Recombinant Antibody Service Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Recombinant Antibody Service Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Recombinant Antibody Service Sales Value Share by Type (2021-2026) Table 21. Global Recombinant Antibody Service Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Biopharmaceuticals Table 23. Significant Companies of Diagnostics Table 24. Significant Companies of Research Table 25. Significant Companies of Therapeutics Table 26. Global Recombinant Antibody Service Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Recombinant Antibody Service Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Recombinant Antibody Service Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Recombinant Antibody Service Sales Value Share by Application (2021-2026) Table 30. Global Recombinant Antibody Service Sales Value Share by Application (2027-2032) Table 31. Global Recombinant Antibody Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Recombinant Antibody Service Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Recombinant Antibody Service Sales Value Share by Region (2021-2026) Table 34. Global Recombinant Antibody Service Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Recombinant Antibody Service Sales Value Share by Region (2027-2032) Table 36. Global Recombinant Antibody Service Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Recombinant Antibody Service Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Recombinant Antibody Service Sales Value Market Share by Country (2021-2026) Table 39. Global Recombinant Antibody Service Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Recombinant Antibody Service Sales Value Market Share by Country (2027-2032) Table 41. GenScript Biotech Corporation Company Information Table 42. GenScript Biotech Corporation Business Overview Table 43. GenScript Biotech Corporation Recombinant Antibody Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. GenScript Biotech Corporation Recombinant Antibody Service Product Portfolio Table 45. GenScript Biotech Corporation Recent Development Table 46. Abcam plc Company Information Table 47. Abcam plc Business Overview Table 48. Abcam plc Recombinant Antibody Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Abcam plc Recombinant Antibody Service Product Portfolio Table 50. Abcam plc Recent Development Table 51. Creative Biolabs Company Information Table 52. Creative Biolabs Business Overview Table 53. Creative Biolabs Recombinant Antibody Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Creative Biolabs Recombinant Antibody Service Product Portfolio Table 55. Creative Biolabs Recent Development Table 56. Absolute Antibody Ltd. Company Information Table 57. Absolute Antibody Ltd. Business Overview Table 58. Absolute Antibody Ltd. Recombinant Antibody Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Absolute Antibody Ltd. Recombinant Antibody Service Product Portfolio Table 60. Absolute Antibody Ltd. Recent Development Table 61. Thermo Fisher Scientific Company Information Table 62. Thermo Fisher Scientific Business Overview Table 63. Thermo Fisher Scientific Recombinant Antibody Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Thermo Fisher Scientific Recombinant Antibody Service Product Portfolio Table 65. Thermo Fisher Scientific Recent Development Table 66. ProteoGenix Company Information Table 67. ProteoGenix Business Overview Table 68. ProteoGenix Recombinant Antibody Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. ProteoGenix Recombinant Antibody Service Product Portfolio Table 70. ProteoGenix Recent Development Table 71. Bio-Rad Laboratories Company Information Table 72. Bio-Rad Laboratories Business Overview Table 73. Bio-Rad Laboratories Recombinant Antibody Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bio-Rad Laboratories Recombinant Antibody Service Product Portfolio Table 75. Bio-Rad Laboratories Recent Development Table 76. Rockland Immunochemicals Inc. Company Information Table 77. Rockland Immunochemicals Inc. Business Overview Table 78. Rockland Immunochemicals Inc. Recombinant Antibody Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Rockland Immunochemicals Inc. Recombinant Antibody Service Product Portfolio Table 80. Rockland Immunochemicals Inc. Recent Development Table 81. RayBiotech, Inc. Company Information Table 82. RayBiotech, Inc. Business Overview Table 83. RayBiotech, Inc. Recombinant Antibody Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. RayBiotech, Inc. Recombinant Antibody Service Product Portfolio Table 85. RayBiotech, Inc. Recent Development Table 86. Novoprotein Scientific Inc. Company Information Table 87. Novoprotein Scientific Inc. Business Overview Table 88. Novoprotein Scientific Inc. Recombinant Antibody Service Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Novoprotein Scientific Inc. Recombinant Antibody Service Product Portfolio Table 90. Novoprotein Scientific Inc. Recent Development Table 91. Sino Biological Company Information Table 92. Sino Biological Business Overview Table 93. Sino Biological Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Sino Biological Recombinant Antibody Service Product Portfolio Table 95. Sino Biological Recent Development Table 96. Abnova Company Information Table 97. Abnova Business Overview Table 98. Abnova Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Abnova Recombinant Antibody Service Product Portfolio Table 100. Abnova Recent Development Table 101. ACROBiosystems Company Information Table 102. ACROBiosystems Business Overview Table 103. ACROBiosystems Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. ACROBiosystems Recombinant Antibody Service Product Portfolio Table 105. ACROBiosystems Recent Development Table 106. Fitzgerald Industries International Company Information Table 107. Fitzgerald Industries International Business Overview Table 108. Fitzgerald Industries International Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Fitzgerald Industries International Recombinant Antibody Service Product Portfolio Table 110. Fitzgerald Industries International Recent Development Table 111. Boster Biological Technology Co., Ltd. Company Information Table 112. Boster Biological Technology Co., Ltd. Business Overview Table 113. Boster Biological Technology Co., Ltd. Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Boster Biological Technology Co., Ltd. Recombinant Antibody Service Product Portfolio Table 115. Boster Biological Technology Co., Ltd. Recent Development Table 116. Azenta Life Sciences Company Information Table 117. Azenta Life Sciences Business Overview Table 118. Azenta Life Sciences Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Azenta Life Sciences Recombinant Antibody Service Product Portfolio Table 120. Azenta Life Sciences Recent Development Table 121. R&D Systems Company Information Table 122. R&D Systems Business Overview Table 123. R&D Systems Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. R&D Systems Recombinant Antibody Service Product Portfolio Table 125. R&D Systems Recent Development Table 126. Abcam Company Information Table 127. Abcam Business Overview Table 128. Abcam Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Abcam Recombinant Antibody Service Product Portfolio Table 130. Abcam Recent Development Table 131. WuXi Biologics Company Information Table 132. WuXi Biologics Business Overview Table 133. WuXi Biologics Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. WuXi Biologics Recombinant Antibody Service Product Portfolio Table 135. WuXi Biologics Recent Development Table 136. Cell Signaling Technology, Inc. Company Information Table 137. Cell Signaling Technology, Inc. Business Overview Table 138. Cell Signaling Technology, Inc. Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Cell Signaling Technology, Inc. Recombinant Antibody Service Product Portfolio Table 140. Cell Signaling Technology, Inc. Recent Development Table 141. Meridian Life Science Inc. Company Information Table 142. Meridian Life Science Inc. Business Overview Table 143. Meridian Life Science Inc. Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. Meridian Life Science Inc. Recombinant Antibody Service Product Portfolio Table 145. Meridian Life Science Inc. Recent Development Table 146. MabPlex Inc. Company Information Table 147. MabPlex Inc. Business Overview Table 148. MabPlex Inc. Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 149. MabPlex Inc. Recombinant Antibody Service Product Portfolio Table 150. MabPlex Inc. Recent Development Table 151. ProMab Biotechnologies Company Information Table 152. ProMab Biotechnologies Business Overview Table 153. ProMab Biotechnologies Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 154. ProMab Biotechnologies Recombinant Antibody Service Product Portfolio Table 155. ProMab Biotechnologies Recent Development Table 156. LakePharma(Curia) Company Information Table 157. LakePharma(Curia) Business Overview Table 158. LakePharma(Curia) Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 159. LakePharma(Curia) Recombinant Antibody Service Product Portfolio Table 160. LakePharma(Curia) Recent Development Table 161. Profacgen Company Information Table 162. Profacgen Business Overview Table 163. Profacgen Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 164. Profacgen Recombinant Antibody Service Product Portfolio Table 165. Profacgen Recent Development Table 166. Atlas Antibodies Company Information Table 167. Atlas Antibodies Business Overview Table 168. Atlas Antibodies Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 169. Atlas Antibodies Recombinant Antibody Service Product Portfolio Table 170. Atlas Antibodies Recent Development Table 171. Proteintech Company Information Table 172. Proteintech Business Overview Table 173. Proteintech Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 174. Proteintech Recombinant Antibody Service Product Portfolio Table 175. Proteintech Recent Development Table 176. BioLegend Company Information Table 177. BioLegend Business Overview Table 178. BioLegend Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 179. BioLegend Recombinant Antibody Service Product Portfolio Table 180. BioLegend Recent Development Table 181. OriGene Technologies Company Information Table 182. OriGene Technologies Business Overview Table 183. OriGene Technologies Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 184. OriGene Technologies Recombinant Antibody Service Product Portfolio Table 185. OriGene Technologies Recent Development Table 186. Biointron Biological Company Information Table 187. Biointron Biological Business Overview Table 188. Biointron Biological Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 189. Biointron Biological Recombinant Antibody Service Product Portfolio Table 190. Biointron Biological Recent Development Table 191. Detai Bio-Tech Company Information Table 192. Detai Bio-Tech Business Overview Table 193. Detai Bio-Tech Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 194. Detai Bio-Tech Recombinant Antibody Service Product Portfolio Table 195. Detai Bio-Tech Recent Development Table 196. FITGENE Company Information Table 197. FITGENE Business Overview Table 198. FITGENE Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 199. FITGENE Recombinant Antibody Service Product Portfolio Table 200. FITGENE Recent Development Table 201. Cusabio Company Information Table 202. Cusabio Business Overview Table 203. Cusabio Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 204. Cusabio Recombinant Antibody Service Product Portfolio Table 205. Cusabio Recent Development Table 206. GentleGen Company Information Table 207. GentleGen Business Overview Table 208. GentleGen Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 209. GentleGen Recombinant Antibody Service Product Portfolio Table 210. GentleGen Recent Development Table 211. TekBiotech Company Information Table 212. TekBiotech Business Overview Table 213. TekBiotech Recombinant Antibody Service Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 214. TekBiotech Recombinant Antibody Service Product Portfolio Table 215. TekBiotech Recent Development Table 216. Research Programs/Design for This Report Table 217. Authors List of This Report Table 218. Secondary Sources Table 219. Primary Sources List of Figures Figure 1. Recombinant Antibody Service Product Image Figure 2. Global Recombinant Antibody Service Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Recombinant Antibody Service Market Size (2021-2032) & (US$ Million) Figure 4. Global Recombinant Antibody Service Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Antibody Discovery & Design Service Image Figure 8. Recombinant Expression Service Image Figure 9. Antibody Purification & Characterization Service Image Figure 10. Global Recombinant Antibody Service Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Recombinant Antibody Service Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Recombinant Antibody Service Sales Value Share by Type (2021-2032) Figure 13. Biopharmaceuticals Image Figure 14. Diagnostics Image Figure 15. Research Image Figure 16. Therapeutics Image Figure 17. Global Recombinant Antibody Service Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Recombinant Antibody Service Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Recombinant Antibody Service Sales Value Share by Application (2021-2032) Figure 20. Global Recombinant Antibody Service Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Recombinant Antibody Service Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Recombinant Antibody Service Sales Value (2021-2032) & (US$ Million) Figure 23. North America Recombinant Antibody Service Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Recombinant Antibody Service Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Recombinant Antibody Service Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Recombinant Antibody Service Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Recombinant Antibody Service Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Recombinant Antibody Service Sales Value (2021-2032) & (US$ Million) Figure 29. South America Recombinant Antibody Service Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Recombinant Antibody Service Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Recombinant Antibody Service Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Recombinant Antibody Service Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Antibody Discovery & Design Service
  • Recombinant Expression Service
  • Antibody Purification & Characterization Service
Applications
  • Biopharmaceuticals
  • Diagnostics
  • Research
  • Therapeutics
Companies covered
  • GenScript Biotech Corporation
  • Abcam plc
  • Creative Biolabs
  • Absolute Antibody Ltd.
  • Thermo Fisher Scientific
  • ProteoGenix
  • Bio-Rad Laboratories
  • Rockland Immunochemicals Inc.
  • RayBiotech, Inc.
  • Novoprotein Scientific Inc.
  • Sino Biological
  • Abnova
  • ACROBiosystems
  • Fitzgerald Industries International
  • Boster Biological Technology Co., Ltd.
  • Azenta Life Sciences
  • R&D Systems
  • Abcam
  • WuXi Biologics
  • Cell Signaling Technology, Inc.
  • Meridian Life Science Inc.
  • MabPlex Inc.
  • ProMab Biotechnologies
  • LakePharma(Curia)
  • Profacgen
  • Atlas Antibodies
  • Proteintech
  • BioLegend
  • OriGene Technologies
  • Biointron Biological
  • Detai Bio-Tech
  • FITGENE
  • Cusabio
  • GentleGen
  • TekBiotech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Recombinant Antibody Service Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Recombinant Antibody Service Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Recombinant Antibody Service Market Dynamics
  1. 2.1 Recombinant Antibody Service Industry Trends
  2. 2.2 Recombinant Antibody Service Industry Drivers
  3. 2.3 Recombinant Antibody Service Industry Opportunities and Challenges
  4. 2.4 Recombinant Antibody Service Industry Restraints
3 Recombinant Antibody Service Market by Company
  1. 3.1 Global Recombinant Antibody Service Company Revenue Ranking in 2025
  2. 3.2 Global Recombinant Antibody Service Revenue by Company (2021-2026)
  3. 3.3 Global Recombinant Antibody Service Company Ranking (2024-2026)
  4. 3.4 Global Recombinant Antibody Service Company Manufacturing Base and Headquarters
  5. 3.5 Global Recombinant Antibody Service Company Product Type and Application
  6. 3.6 Global Recombinant Antibody Service Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Recombinant Antibody Service Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Recombinant Antibody Service Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Recombinant Antibody Service Market by Type
  1. 4.1 Recombinant Antibody Service Type Introduction
  2. 4.1.1 Antibody Discovery & Design Service
  3. 4.1.2 Recombinant Expression Service
  4. 4.1.3 Antibody Purification & Characterization Service
  5. 4.2 Global Recombinant Antibody Service Sales Value by Type
  6. 4.2.1 Global Recombinant Antibody Service Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Recombinant Antibody Service Sales Value by Type (2021-2032)
  8. 4.2.3 Global Recombinant Antibody Service Sales Value Share by Type (2021-2032)
5 Recombinant Antibody Service Market by Application
  1. 5.1 Recombinant Antibody Service Application Introduction
  2. 5.1.1 Biopharmaceuticals
  3. 5.1.2 Diagnostics
  4. 5.1.3 Research
  5. 5.1.4 Therapeutics
  6. 5.2 Global Recombinant Antibody Service Sales Value by Application
  7. 5.2.1 Global Recombinant Antibody Service Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Recombinant Antibody Service Sales Value by Application (2021-2032)
  9. 5.2.3 Global Recombinant Antibody Service Sales Value Share by Application (2021-2032)
6 Recombinant Antibody Service Regional Value Analysis
  1. 6.1 Global Recombinant Antibody Service Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Recombinant Antibody Service Sales Value by Region (2021-2032)
  3. 6.2.1 Global Recombinant Antibody Service Sales Value by Region: 2021-2026
  4. 6.2.2 Global Recombinant Antibody Service Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Recombinant Antibody Service Sales Value (2021-2032)
  7. 6.3.2 North America Recombinant Antibody Service Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Recombinant Antibody Service Sales Value (2021-2032)
  10. 6.4.2 Europe Recombinant Antibody Service Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Recombinant Antibody Service Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Recombinant Antibody Service Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Recombinant Antibody Service Sales Value (2021-2032)
  16. 6.6.2 South America Recombinant Antibody Service Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Recombinant Antibody Service Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Recombinant Antibody Service Sales Value Share by Country, 2025 VS 2032
7 Recombinant Antibody Service Country-level Value Analysis
  1. 7.1 Global Recombinant Antibody Service Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Recombinant Antibody Service Sales Value by Country (2021-2032)
  3. 7.2.1 Global Recombinant Antibody Service Sales Value by Country (2021-2026)
  4. 7.2.2 Global Recombinant Antibody Service Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Recombinant Antibody Service Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Recombinant Antibody Service Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Recombinant Antibody Service Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GenScript Biotech Corporation
  2. 8.1.1 GenScript Biotech Corporation Company Information
  3. 8.1.2 GenScript Biotech Corporation Business Overview
  4. 8.1.3 GenScript Biotech Corporation Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  5. 8.1.4 GenScript Biotech Corporation Recombinant Antibody Service Product Portfolio
  6. 8.1.5 GenScript Biotech Corporation Recent Developments
  7. 8.2 Abcam plc
  8. 8.2.1 Abcam plc Company Information
  9. 8.2.2 Abcam plc Business Overview
  10. 8.2.3 Abcam plc Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Abcam plc Recombinant Antibody Service Product Portfolio
  12. 8.2.5 Abcam plc Recent Developments
  13. 8.3 Creative Biolabs
  14. 8.3.1 Creative Biolabs Company Information
  15. 8.3.2 Creative Biolabs Business Overview
  16. 8.3.3 Creative Biolabs Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Creative Biolabs Recombinant Antibody Service Product Portfolio
  18. 8.3.5 Creative Biolabs Recent Developments
  19. 8.4 Absolute Antibody Ltd.
  20. 8.4.1 Absolute Antibody Ltd. Company Information
  21. 8.4.2 Absolute Antibody Ltd. Business Overview
  22. 8.4.3 Absolute Antibody Ltd. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Absolute Antibody Ltd. Recombinant Antibody Service Product Portfolio
  24. 8.4.5 Absolute Antibody Ltd. Recent Developments
  25. 8.5 Thermo Fisher Scientific
  26. 8.5.1 Thermo Fisher Scientific Company Information
  27. 8.5.2 Thermo Fisher Scientific Business Overview
  28. 8.5.3 Thermo Fisher Scientific Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Thermo Fisher Scientific Recombinant Antibody Service Product Portfolio
  30. 8.5.5 Thermo Fisher Scientific Recent Developments
  31. 8.6 ProteoGenix
  32. 8.6.1 ProteoGenix Company Information
  33. 8.6.2 ProteoGenix Business Overview
  34. 8.6.3 ProteoGenix Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  35. 8.6.4 ProteoGenix Recombinant Antibody Service Product Portfolio
  36. 8.6.5 ProteoGenix Recent Developments
  37. 8.7 Bio-Rad Laboratories
  38. 8.7.1 Bio-Rad Laboratories Company Information
  39. 8.7.2 Bio-Rad Laboratories Business Overview
  40. 8.7.3 Bio-Rad Laboratories Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Bio-Rad Laboratories Recombinant Antibody Service Product Portfolio
  42. 8.7.5 Bio-Rad Laboratories Recent Developments
  43. 8.8 Rockland Immunochemicals Inc.
  44. 8.8.1 Rockland Immunochemicals Inc. Company Information
  45. 8.8.2 Rockland Immunochemicals Inc. Business Overview
  46. 8.8.3 Rockland Immunochemicals Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Rockland Immunochemicals Inc. Recombinant Antibody Service Product Portfolio
  48. 8.8.5 Rockland Immunochemicals Inc. Recent Developments
  49. 8.9 RayBiotech, Inc.
  50. 8.9.1 RayBiotech, Inc. Company Information
  51. 8.9.2 RayBiotech, Inc. Business Overview
  52. 8.9.3 RayBiotech, Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  53. 8.9.4 RayBiotech, Inc. Recombinant Antibody Service Product Portfolio
  54. 8.9.5 RayBiotech, Inc. Recent Developments
  55. 8.10 Novoprotein Scientific Inc.
  56. 8.10.1 Novoprotein Scientific Inc. Company Information
  57. 8.10.2 Novoprotein Scientific Inc. Business Overview
  58. 8.10.3 Novoprotein Scientific Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novoprotein Scientific Inc. Recombinant Antibody Service Product Portfolio
  60. 8.10.5 Novoprotein Scientific Inc. Recent Developments
  61. 8.11 Sino Biological
  62. 8.11.1 Sino Biological Company Information
  63. 8.11.2 Sino Biological Business Overview
  64. 8.11.3 Sino Biological Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Sino Biological Recombinant Antibody Service Product Portfolio
  66. 8.11.5 Sino Biological Recent Developments
  67. 8.12 Abnova
  68. 8.12.1 Abnova Company Information
  69. 8.12.2 Abnova Business Overview
  70. 8.12.3 Abnova Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Abnova Recombinant Antibody Service Product Portfolio
  72. 8.12.5 Abnova Recent Developments
  73. 8.13 ACROBiosystems
  74. 8.13.1 ACROBiosystems Company Information
  75. 8.13.2 ACROBiosystems Business Overview
  76. 8.13.3 ACROBiosystems Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  77. 8.13.4 ACROBiosystems Recombinant Antibody Service Product Portfolio
  78. 8.13.5 ACROBiosystems Recent Developments
  79. 8.14 Fitzgerald Industries International
  80. 8.14.1 Fitzgerald Industries International Company Information
  81. 8.14.2 Fitzgerald Industries International Business Overview
  82. 8.14.3 Fitzgerald Industries International Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Fitzgerald Industries International Recombinant Antibody Service Product Portfolio
  84. 8.14.5 Fitzgerald Industries International Recent Developments
  85. 8.15 Boster Biological Technology Co., Ltd.
  86. 8.15.1 Boster Biological Technology Co., Ltd. Company Information
  87. 8.15.2 Boster Biological Technology Co., Ltd. Business Overview
  88. 8.15.3 Boster Biological Technology Co., Ltd. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Boster Biological Technology Co., Ltd. Recombinant Antibody Service Product Portfolio
  90. 8.15.5 Boster Biological Technology Co., Ltd. Recent Developments
  91. 8.16 Azenta Life Sciences
  92. 8.16.1 Azenta Life Sciences Company Information
  93. 8.16.2 Azenta Life Sciences Business Overview
  94. 8.16.3 Azenta Life Sciences Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Azenta Life Sciences Recombinant Antibody Service Product Portfolio
  96. 8.16.5 Azenta Life Sciences Recent Developments
  97. 8.17 R&D Systems
  98. 8.17.1 R&D Systems Company Information
  99. 8.17.2 R&D Systems Business Overview
  100. 8.17.3 R&D Systems Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  101. 8.17.4 R&D Systems Recombinant Antibody Service Product Portfolio
  102. 8.17.5 R&D Systems Recent Developments
  103. 8.18 Abcam
  104. 8.18.1 Abcam Company Information
  105. 8.18.2 Abcam Business Overview
  106. 8.18.3 Abcam Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Abcam Recombinant Antibody Service Product Portfolio
  108. 8.18.5 Abcam Recent Developments
  109. 8.19 WuXi Biologics
  110. 8.19.1 WuXi Biologics Company Information
  111. 8.19.2 WuXi Biologics Business Overview
  112. 8.19.3 WuXi Biologics Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  113. 8.19.4 WuXi Biologics Recombinant Antibody Service Product Portfolio
  114. 8.19.5 WuXi Biologics Recent Developments
  115. 8.20 Cell Signaling Technology, Inc.
  116. 8.20.1 Cell Signaling Technology, Inc. Company Information
  117. 8.20.2 Cell Signaling Technology, Inc. Business Overview
  118. 8.20.3 Cell Signaling Technology, Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Cell Signaling Technology, Inc. Recombinant Antibody Service Product Portfolio
  120. 8.20.5 Cell Signaling Technology, Inc. Recent Developments
  121. 8.21 Meridian Life Science Inc.
  122. 8.21.1 Meridian Life Science Inc. Company Information
  123. 8.21.2 Meridian Life Science Inc. Business Overview
  124. 8.21.3 Meridian Life Science Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  125. 8.21.4 Meridian Life Science Inc. Recombinant Antibody Service Product Portfolio
  126. 8.21.5 Meridian Life Science Inc. Recent Developments
  127. 8.22 MabPlex Inc.
  128. 8.22.1 MabPlex Inc. Company Information
  129. 8.22.2 MabPlex Inc. Business Overview
  130. 8.22.3 MabPlex Inc. Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  131. 8.22.4 MabPlex Inc. Recombinant Antibody Service Product Portfolio
  132. 8.22.5 MabPlex Inc. Recent Developments
  133. 8.23 ProMab Biotechnologies
  134. 8.23.1 ProMab Biotechnologies Company Information
  135. 8.23.2 ProMab Biotechnologies Business Overview
  136. 8.23.3 ProMab Biotechnologies Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  137. 8.23.4 ProMab Biotechnologies Recombinant Antibody Service Product Portfolio
  138. 8.23.5 ProMab Biotechnologies Recent Developments
  139. 8.24 LakePharma(Curia)
  140. 8.24.1 LakePharma(Curia) Company Information
  141. 8.24.2 LakePharma(Curia) Business Overview
  142. 8.24.3 LakePharma(Curia) Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  143. 8.24.4 LakePharma(Curia) Recombinant Antibody Service Product Portfolio
  144. 8.24.5 LakePharma(Curia) Recent Developments
  145. 8.25 Profacgen
  146. 8.25.1 Profacgen Company Information
  147. 8.25.2 Profacgen Business Overview
  148. 8.25.3 Profacgen Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Profacgen Recombinant Antibody Service Product Portfolio
  150. 8.25.5 Profacgen Recent Developments
  151. 8.26 Atlas Antibodies
  152. 8.26.1 Atlas Antibodies Company Information
  153. 8.26.2 Atlas Antibodies Business Overview
  154. 8.26.3 Atlas Antibodies Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Atlas Antibodies Recombinant Antibody Service Product Portfolio
  156. 8.26.5 Atlas Antibodies Recent Developments
  157. 8.27 Proteintech
  158. 8.27.1 Proteintech Company Information
  159. 8.27.2 Proteintech Business Overview
  160. 8.27.3 Proteintech Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Proteintech Recombinant Antibody Service Product Portfolio
  162. 8.27.5 Proteintech Recent Developments
  163. 8.28 BioLegend
  164. 8.28.1 BioLegend Company Information
  165. 8.28.2 BioLegend Business Overview
  166. 8.28.3 BioLegend Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  167. 8.28.4 BioLegend Recombinant Antibody Service Product Portfolio
  168. 8.28.5 BioLegend Recent Developments
  169. 8.29 OriGene Technologies
  170. 8.29.1 OriGene Technologies Company Information
  171. 8.29.2 OriGene Technologies Business Overview
  172. 8.29.3 OriGene Technologies Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  173. 8.29.4 OriGene Technologies Recombinant Antibody Service Product Portfolio
  174. 8.29.5 OriGene Technologies Recent Developments
  175. 8.30 Biointron Biological
  176. 8.30.1 Biointron Biological Company Information
  177. 8.30.2 Biointron Biological Business Overview
  178. 8.30.3 Biointron Biological Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  179. 8.30.4 Biointron Biological Recombinant Antibody Service Product Portfolio
  180. 8.30.5 Biointron Biological Recent Developments
  181. 8.31 Detai Bio-Tech
  182. 8.31.1 Detai Bio-Tech Company Information
  183. 8.31.2 Detai Bio-Tech Business Overview
  184. 8.31.3 Detai Bio-Tech Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  185. 8.31.4 Detai Bio-Tech Recombinant Antibody Service Product Portfolio
  186. 8.31.5 Detai Bio-Tech Recent Developments
  187. 8.32 FITGENE
  188. 8.32.1 FITGENE Company Information
  189. 8.32.2 FITGENE Business Overview
  190. 8.32.3 FITGENE Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  191. 8.32.4 FITGENE Recombinant Antibody Service Product Portfolio
  192. 8.32.5 FITGENE Recent Developments
  193. 8.33 Cusabio
  194. 8.33.1 Cusabio Company Information
  195. 8.33.2 Cusabio Business Overview
  196. 8.33.3 Cusabio Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  197. 8.33.4 Cusabio Recombinant Antibody Service Product Portfolio
  198. 8.33.5 Cusabio Recent Developments
  199. 8.34 GentleGen
  200. 8.34.1 GentleGen Company Information
  201. 8.34.2 GentleGen Business Overview
  202. 8.34.3 GentleGen Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  203. 8.34.4 GentleGen Recombinant Antibody Service Product Portfolio
  204. 8.34.5 GentleGen Recent Developments
  205. 8.35 TekBiotech
  206. 8.35.1 TekBiotech Company Information
  207. 8.35.2 TekBiotech Business Overview
  208. 8.35.3 TekBiotech Recombinant Antibody Service Revenue and Gross Margin (2021-2026)
  209. 8.35.4 TekBiotech Recombinant Antibody Service Product Portfolio
  210. 8.35.5 TekBiotech Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst